[Roncoleukin immunomodulation in pulmonary tuberculosis].
The effects of roncoleukine (recombinant human interleukin-2) on clinical and immunological parameters were studied in patients with pulmonary tuberculosis. Twenty five patients with fibrocavernous pulmonary tuberculosis steadily progressive during the therapy were examined. Roncoleukine caused no complications and its clinical effect was recorded in 80.8% of cases. Changed immunological parameters noticeably tended to become normal. The increase in the baseline lower cellular immunological parameters was most pronounced. The paper shows it expedient to use roncoleukine as an immunomodulator in the treatment of severe pulmonary tuberculosis.
Knoring
B E
BE
El'kin
A V
AV
Smirnov
M N
MN
Sakharova
I Ia
IIa
Basek
T S
TS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D015703:Antigens, CD / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D016516:CD4-CD8 Ratio; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007376:Interleukin-2 / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D007136:Immunoglobulins; D007376:Interleukin-2; D011994:Recombinant Proteins